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Background
The protozoan Trypanosoma cruzi is the causative agent of 
Chagas disease and is the most important parasite in Latin 
America, infecting 10 million people.1 Throughout endemic 
regions, it is a leading cause of premature heart disease. The 
parasite is spread primarily by blood-sucking triatomine 
bugs, although other means of transmission include the con-
genital route, contaminated food and drink, organ trans-
plantation, and blood transfusion. Due to increased mobility 
and migration, the disease is also appearing in nonendemic 
regions. There are estimated to be 300,000 infected indi-
viduals in the United States2 and 80,000 in Europe.3
Chagas disease can be divided into distinct stages. The 
“acute” stage is usually relatively mild and often undiagnosed. 
In children, the infection can be more severe, presenting as a 
febrile illness, with death from meningoencephalitis or myo-
carditis in up to 5% of diagnosed cases. With the development 
of an adaptive immune response, parasitemia is suppressed, 
although sterile immunity is not achieved. This “indetermi-
nate” stage is asymptomatic and can be lifelong, with parasites 
difficult to detect. Around 30% of infected individuals proceed 
to the “chronic” stage, sometimes decades later.4 This phase is 
characterized by clinical manifestations, including cardiomy-
opathy and, more rarely, damage to the digestive tract (mainly 
megacolon and megaesophagus) and/or lesions in the periph-
eral nervous system.
T. cruzi is an obligate intracellular parasite and can invade 
many mammalian cell types, including smooth and cardiac 
muscle cells, macrophages, and neurons. Both innate and 
adaptive immune responses are activated by infection.5–7 
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Abstract
The protozoan Trypanosoma cruzi is the causative agent of Chagas disease, one of the world’s major neglected infections. 
Although development of improved antiparasitic drugs is considered a priority, there have been no significant treatment 
advances in the past 40 years. Factors that have limited progress include an incomplete understanding of pathogenesis, tissue 
tropism, and disease progression. In addition, in vivo models, which allow parasite burdens to be tracked throughout the 
chronic stage of infection, have been lacking. To address these issues, we have developed a highly sensitive in vivo imaging 
system based on bioluminescent T. cruzi, which express a red-shifted luciferase that emits light in the tissue-penetrating 
orange-red region of the spectrum. The exquisite sensitivity of this noninvasive murine model has been exploited to 
monitor parasite burden in real time throughout the chronic stage, has allowed the identification of the gastrointestinal 
tract as the major niche of long-term infection, and has demonstrated that chagasic heart disease can develop in the 
absence of locally persistent parasites. Here, we review the parameters of the imaging system and describe how this 
experimental model can be incorporated into drug development programs as a valuable tool for assessing efficacy against 
both acute and chronic T. cruzi infections.
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Chagas disease is also characterized by induction of nonspe-
cific polyclonal B-cell and T-cell responses, some of which 
may be autoreactive.8,9 These findings have prompted a long-
standing debate about whether chronic stage cardiac disease 
results from autoimmune mechanisms or from inflammatory 
immune responses driven by parasite persistence within the 
heart and other organs.10–13
Because of the long-term nature of Chagas disease and 
its complex pathology, there is no realistic prospect of a 
vaccine in the foreseeable future. For treatment of T. cruzi 
infections, only two drugs are currently available, the nitro-
heterocyclic compounds nifurtimox and benznidazole.14 In 
each case, however, long-term therapeutic schedules are 
required, and toxic side effects are frequently observed. 
Although effective against acute stage infections, their abil-
ity to prevent the development of chronic chagasic heart 
disease is unresolved.14,15 Both nifurtimox and benznida-
zole are prodrugs and are activated by the same mitochon-
drial nitroreductase,16,17 a phenomenon with potential to 
result in cross-resistance. This, coupled with frequent 
reports of treatment failure, makes the development of new 
drugs a major priority.
Bioluminescence Imaging
It has been almost a decade since noninvasive biolumines-
cence imaging technology was first used as a tool for study-
ing protozoan infections.18 The approach requires the 
generation of genetically modified parasites capable of 
expressing luciferase.19,20 This class of enzyme oxidizes a 
luciferin substrate by an adenosine triphosphate (ATP)–
dependent mechanism, resulting in light emission. Using an 
appropriate in vivo imaging system, parasite location within 
the infected host (almost invariably a mouse) can then be 
inferred and monitored in real time by detection of the sig-
nal. This procedure has been a powerful addition to the 
range of techniques applicable to infectious disease 
research.21 Importantly, whole-body bioluminescence can 
also be directly correlated with parasite load and provides a 
simple, noninvasive method for quantifying therapeutic 
intervention. Moreover, the ability to serially evaluate indi-
vidual animals provides richer and more relevant data sets, 
while simultaneously enabling a drastic reduction in the 
number of animals required.
Most of the bioluminescence imaging systems applied to 
trypanosomatids18,22–33 have used reporter enzymes, such as 
firefly luciferase, which emit light in the blue-green region of 
the spectrum. One factor that has restricted their wider utility 
is the significant reduction in optical resolution that occurs at 
this wavelength (<600 nm) when parasites are situated deep 
within the viscera.21 This loss of sensitivity results from 
absorption and scattering of the emitted light. In the case of 
the former, hemoglobin is the primary chromophore, with 
absorbance occurring mainly in the region of the spectrum 
that overlaps with the light emitted in the luciferase reactions. 
With light scatter, the effect is also greater at shorter wave-
lengths. In combination, these factors result in blue-green 
light having restricted tissue penetration. To overcome these 
optical limitations, bioluminescent reporters that emit light 
above 600 nm have been engineered for in vivo imaging.34,35 
As an example of the enhanced level of sensitivity that is now 
achievable, we have generated transgenic African trypano-
somes expressing a red-shifted firefly luciferase (emission 
maximum changed from 562 nm to 617 nm), where the limit 
of detection is less than 100 parasites in an inoculated 
mouse.36,37 This is an improvement of up to three orders of 
magnitude on previously described reporter systems.
Optimizing In Vivo Imaging of  
T. cruzi Infections
Several murine models that mimic aspects of human Chagas 
disease are available and have been widely used.38–41 
However, predictive experimental systems that enable dis-
ease pathology to be matched to both the level and distribu-
tion of parasite burden during drug treatment have been 
lacking. This has limited our ability to identify the determi-
nants of pathology and to assess drug treatment in real time. 
In chronic T. cruzi infection models, parasitemia is gener-
ally subpatent, and nondividing extracellular trypomasti-
gotes are only rarely detected in the blood by standard 
microscopy procedures. One of our aims, therefore, was to 
develop an experimental model that would allow parasite 
dissemination and tissue tropism to be monitored in a non-
invasive manner throughout chronic stage infections.
First, we designed a DNA construct to integrate the 
PpyRE9h thermostable red-shifted luciferase gene35,36 into 
the multicopy ribosomal locus of the parasite, so that tran-
scription would be under the control of an RNA polymerase 
I–dependent promoter and its associated downstream termi-
nation sequences42 (Fig. 1A). Trypanosomes are unusual in 
allowing integrated protein coding genes to be expressed in 
this context, and previous studies had demonstrated that 
high levels of transcription are achievable from ribosomal 
loci.43 When transgenic parasites were subsequently ana-
lyzed, we found considerable variation in the level of lucif-
erase expression between different clones selected from the 
same transfection, a phenomenon that may be associated 
with locus-specific epigenetic regulation. However, once 
highly expressing parasite clones were isolated, the level of 
bioluminescence remained consistent between parasites in 
the population (Fig. 1B) and was stable over time. Parasites 
maintained for more than 300 days in absence of G418, the 
drug used to select transfectants, displayed unaltered levels 
of bioluminescence.44 In addition, there was no significant 
variation in the level of expression between the differing 
life cycle stages. Importantly, these parasites displayed 
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growth and virulence properties that were indistinguishable 
from the parental CL Brener strain.
For in vivo imaging experiments, we normally inoculate 
mice by the intraperitoneal (i.p.) route, using bloodstream 
trypomastigotes derived from infected immunodeficient 
SCID mice. At defined time points thereafter, mice are 
injected with d-luciferin (Fig. 1C) and imaged 10 to 20 min 
later (Fig. 1D). Under these conditions, the limit of detec-
tion by in vivo imaging is close to 100 parasites (Fig. 2A,B), 
with a linear relationship between parasite load and whole-
body bioluminescence at 1000 parasites and above44 (Fig. 
2C). To put this into context, a single infected mammalian 
cell can contain several hundred amastigotes.
In Vivo Imaging Provides New Insights 
into Chronic T. cruzi Infections
With this bioluminescence imaging system, which is at least 
102-fold more sensitive than others reported previ-
ously,22,26,28,33 it was possible for the first time to track T. 
cruzi distribution in an individual mouse for more than a 
year throughout a long-term chronic infection (Fig. 3A,B). 
In the BALB/c model, following i.p. inoculation with 103 
bloodstream trypomastigotes (CL Brener strain), total bio-
luminescence peaked 14 days postinfection, with parasites 
widely disseminated, infecting all of the major organs, 
including the heart (Fig. 3C). The ubiquitous detection of 
bioluminescence, which could be correlated with parasite 
burden by tissue-specific quantitative PCR (qPCR),44 sug-
gests that the bioavailability of d-luciferin is not a limiting 
factor in application of the technology. This peak in parasite 
burden during the acute stage was followed by a progres-
sive decrease and elimination from most tissues, with para-
sites microscopically undetectable in blood smears by day 
35.44 As infections entered the chronic stage, total parasite 
levels were up to 1000 times lower than in the acute stage, 
although highly dynamic bioluminescent foci could be 
detected that fluctuated in a spatiotemporally dynamic man-
ner (Fig. 3A,B). Typically during the chronic stage, between 
1 and 5 specific infection foci could be observed in each 
animal, with these appearing and disappearing over a 24- to 
48-h period. This pattern was independent of the route of 
inoculation (i.p., intravenous [i.v.], or subcutaneous [s.c.]) 
or the type of infectious parasite used to initiate the infec-
tion (metacyclic, bloodstream-form, or tissue culture–
derived trypomastigotes). Given the short-term nature of 
these bioluminescent foci and the sensitivity of the imaging 
system, the most likely explanation is that they represent 
single infected phagocytes that become detectable as they 
are trafficked to peripheral sites.
To gain a more definitive assessment of tissue-specific 
parasite burdens, ex vivo imaging of selected organs and tis-
sue samples can be undertaken immediately postmortem. 
When BALB/c mice in the chronic stage of infection were 
analyzed using this approach, parasites were consistently 
found to be restricted to the gastrointestinal tract (GIT), 
Figure 1. In vivo imaging of Trypanosoma cruzi. (A) The vector pTRIX2-RE9h44 was constructed by inserting the red-shifted firefly 
luciferase variant gene PpyRE9h35 into the T. cruzi rDNA targeting plasmid pTRIX.50 For transfection, the linearized targeting fragment 
can be produced by digesting the vector with the restriction enzymes indicated by arrows. (B) Cloned pTRIX2-RE9h–transfected T. 
cruzi epimastigotes, paraformaldehyde fixed and stained with anti–luciferase polyclonal antibody. Parasite DNA is stained red with 
Hoechst 33342. (C) Standard procedure for in vivo imaging experiments. Mice can be infected with bioluminescent parasites by the 
intraperitoneal, intravenous, or subcutaneous routes. At defined time points thereafter, they are inoculated with 150 mg–1 kg–1 d-luciferin, 
anaesthetized, and imaged for up to 5 min using an IVIS Lumina II system (PerkinElmer, Seer Green, UK).44 (D) Establishing the optimal 
“imaging window.” The variation in total ventral bioluminescence flux over time following injection of the luciferin substrate is shown.
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mainly localized to the colon and/or stomach (Fig. 3C). 
Minor infection foci were detected in the gut mesenteries or 
skeletal muscle on some occasions but surprisingly not in the 
heart, the main site of disease pathology. Despite the absence 
of locally persistent heart infection in this model, mice dis-
played signatures of chagasic cardiac pathology, including 
infiltration with inflammatory mononuclear cells, mild 
edema, and fibrosis.44 The absence of parasites in heart tissue 
and their persistent presence in the GIT were confirmed by a 
highly sensitive qPCR-based DNA detection assay.
These observations provide new insights into T. cruzi 
infection and the processes underlying disease pathology. 
Figure 3. Imaging the development of chronic Trypanosoma cruzi infections. (A) Ventral and dorsal images of the same individual 
BALB/c mouse infected with PpyRE9h-expressing T. cruzi imaged at the indicated day postinfection (dpi) over the course of >1 year. 
(B) Quantification of combined ventral and dorsal bioluminescence for the mouse shown in A. Gray line and dashed line are the 
mean and mean +2 SDs, respectively, for uninfected control mice. (C) Ex vivo bioluminescence analysis of selected organs and tissue 
samples imaged immediately postmortem. An example is shown for acute (14 dpi) and chronic (167 dpi) infection. 1, lung; 2, heart; 3, 
visceral adipose; 4, skeletal muscle (quadriceps); 5, spleen; 6, gut mesenteries; 7, stomach; 8, small intestine; 9, large intestine.
Figure 2. Highly sensitive in vivo 
imaging achieved with red-shifted 
luciferase. (A) Ventral images of 
SCID mice 1 h after intraperitoneal 
injection with bioluminescent 
bloodstream trypomastigotes (CL 
Brener strain, numbers indicated). 
The bioluminescence intensity is based 
on a log10 scale heatmap as indicated 
(right). (B) Abdominal bioluminescence 
displayed by mice 1 h after infection 
with 100 or 1000 bloodstream 
trypomastigotes. The regions used for 
signal quantification are outlined by the 
red circles in A. (C) Quantification of 
abdominal bioluminescence for mice 
shown in A. Dotted line represents 
background +2 SD. Figure adapted from 
Lewis et al.44
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First, they implicate the GIT as a permissive niche that acts 
as a parasite reservoir, allowing long-term parasite persis-
tence. Second, they suggest a mechanism that facilitates 
disease transmission by ensuring continual migration of 
parasite-infected cells to peripheral sites where they become 
accessible to triatomine vectors during a blood meal. Third, 
they provide evidence that locally persistent infection of the 
heart during chronic infection is not an essential require-
ment for the development of cardiac pathology during 
chronic T. cruzi infections.
An Improved Experimental Model for 
Assessing Drug Efficacy
Attempts to assess the efficacy of new drugs against Chagas 
disease are made complex by the long-term nature of the 
disease in humans (which can stretch over decades) and dif-
ficulties in demonstrating parasitological cure during the 
chronic stage. In experimental animal models, continuous 
monitoring of parasite burden is also difficult to achieve 
because bloodstream infections are generally subpatent and 
tissue sampling requires animals to be sacrificed at each 
time point. While PCR-based methodologies benefit from 
high sensitivity, reproducibility has often been a problem. 
This is now understandable given the discrete locations of 
infection foci and their highly dynamic nature (Fig. 3). The 
advances in imaging technology described above therefore 
provide a basis for developing improved predictive models 
for drug development programs. This can be demonstrated 
by monitoring the effectiveness of benznidazole therapy 
against both acute and chronic infections.
When immunodeficient SCID mice are inoculated with 
T. cruzi, there is a widely disseminated infection (Fig. 4A) 
that causes a rapidly progressive cachexia-like syndrome. 
Humane end points are typically reached within 3 to 4 
weeks depending on the inoculum. We treated mice with 
oral benznidazole (100 mg/kg–1), starting 14 days postinfec-
tion (Fig. 4A), and observed a progressive reduction in 
parasitemia over the 5-day treatment schedule, as assessed 
by in vivo imaging. This correlated with improvements in 
animal condition and the reversion of parasitemia to sub-
patent levels. However, when mice were first judged as 
clear by microscopic examination of peripheral blood sam-
ples, parasites remained readily detectable by biolumines-
cence (e.g., day 18; Fig. 4A). Similarly, the sensitivity of 
the in vivo imaging system has provided a means of moni-
toring the effectiveness of therapy against chronic T. cruzi 
infections in an experimental model of Chagas disease, 
when parasites are rarely visualized in the bloodstream. As 
a shown in Figure 4B,C, the approach allows the real-time 
evaluation of treatment in BALB/c mice in a manner that 
should be scalable to the needs of a drug development 
pipeline.
The most challenging aspect for the development of pre-
dictive treatment models, and one that is by no means 
unique to Chagas disease research, is the capacity to 
unequivocally demonstrate sterile cure. In the absence of 
definitive cure criteria, a number of proxy measures are 
Figure 4. Validation of in vivo imaging as a tool to assess efficacy of drug treatment against acute and chronic Trypanosoma cruzi 
infections. (A) SCID mice infected with 103 bioluminescent T. cruzi bloodstream trypomastigotes (CL Brener strain) were treated 
(T) with benznidazole (daily by oral route, 100 mg–1/kg–1) 14 to 19 days postinfection (dpi) and compared with control nontreated 
(NT) mice. The bioluminescence intensity is represented by a log10 scale heatmap as indicated (right). (B) BALB/c mice chronically 
infected with bioluminescent T. cruzi were treated (T) for 5 days with 100 mg–1/kg–1 benznidazole by the oral route starting at 66 dpi 
and compared with control nontreated (NT) mice. The bioluminescence intensity is represented by a linear scale heatmap as indicated 
(right). (C) Quantification of total ventral bioluminescence for the experiment including the mice shown in B (n = 3). Gray line and 
dashed line are the mean and mean +2 SDs, respectively, for uninfected control mice. Red arrows indicate treatment days.
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commonly used, including fresh blood examination, blood 
cultures, inoculation of immunocompromised animals with 
blood samples, PCR on DNA from blood and tissue sam-
ples, and serological assays. Tissue PCR is understandably 
the most sensitive of these traditional approaches and can 
identify a significant number of noncured mice that would 
otherwise appear as cured on blood-based criteria.45 The 
insight into the dynamics of T. cruzi infection provided by 
bioluminescence imaging shows that even tissue PCR is 
likely to misclassify treatment failures as cures, due to the 
highly focal distribution of parasites. The immunosuppres-
sive drug cyclophosphamide has been used to enhance post-
treatment parasite detection sensitivity,46–48 the rationale for 
this being that residual foci of infection are allowed to 
expand to detectable levels when adaptive immunity is 
compromised. Thus, combining cyclophosphamide treat-
ment with bioluminescence imaging should provide a maxi-
mally sensitive approach to assess cure and relapse.
Cyclophosphamide has toxic side effects and increases the 
risk of secondary infections, so it is important to implement 
appropriate monitoring procedures. It is also necessary to tai-
lor immunosuppression protocols to particular host-parasite 
strain combinations. For example, two alternative treatment 
schedules have been described.46,49 Preliminary testing in our 
laboratory on BALB/c mice chronically infected with the 
PpyRE9h-expressing CL Brener strain has shown that immu-
nosuppression does lead to an increase in bioluminescence 
(Fig. 5), although neither protocol caused reversion to patent 
parasitemia. We were also able to demonstrate that treatment 
with 100 mg-1 kg-1 benznidazole daily for 20 days results in 
sterile cure, whereas treatment with 10 mg-1 kg-1 does not, 
even though parasite burden falls transiently below the level 
of detection (Fig. 5 as an example). Integrating posttreatment 
immunosuppression and bioluminescence imaging should 
therefore provide a method to evaluate the true dynamics of 
T. cruzi reactivation and dissemination in animals that are 
treated but not cured.
In conclusion, drug development for Chagas disease has 
been hampered by a lack of sufficiently sensitive tools for the 
detection of parasites that remain following drug treatment of 
experimental infections. Highly sensitive in vivo imaging 
models using transgenic bioluminescent T. cruzi parasites 
therefore represent an important advance. This technology is 
reproducible, is relatively scalable, and can be adapted to 
diverse experimental schedules and models. Furthermore, 
serial imaging of individual animals means the data generated 
are more robust yet require far fewer experimental animals 
than with traditional methods. It is important to recognize that 
bioluminescence imaging alone will not provide a definitive 
measure of sterile cure, but when combined with posttreatment 
immunosuppression, it will provide a drastically improved 
approach to evaluate the efficacy of novel therapeutic com-
pounds for the treatment of T. cruzi infections.
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Figure 5. Combining in vivo imaging and immunosuppression 
to monitor the effectiveness of benznidazole treatment. 
Ventral views of BALB/c mice infected with 103 bioluminescent 
Trypanosoma cruzi bloodstream trypomastigotes and treated 
with benznidazole. (A) Nontreated control. (B) Nontreated, 
immunosuppressed with 200 mg-1 kg-1 cyclophosphamide 
by intraperitoneal injection 124, 127, 130, and 133 days 
postinfection (dpi). (C) Treated with daily oral doses of 
10 mg-1 kg-1 benznidazole between 90 and 110 dpi, then 
immunosuppressed with cyclophosphamide as above. (D) 
Treated with daily oral doses of 100 mg-1 kg-1 benznidazole 
between 90 and 110 dpi, then immunosuppressed with 
cyclophosphamide. The bioluminescence intensity is represented 
by a linear scale heatmap as indicated (left).
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